{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:48:42Z","timestamp":1783572522840,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T00:00:00Z","timestamp":1665273600000},"content-version":"am","delay-in-days":312,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010638","name":"Huntsman Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA042014"],"award-info":[{"award-number":["P30 CA042014"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.canep.2021.102045","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T08:32:05Z","timestamp":1634027525000},"page":"102045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry"],"prefix":"10.1016","volume":"75","author":[{"given":"Nicholas","family":"Pavlidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-0991","authenticated-orcid":false,"given":"Elie","family":"Rassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan B.","family":"Vermorken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Assi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-6131","authenticated-orcid":false,"given":"Stergios","family":"Boussios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Smith-Gagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2021.102045_bib1","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site","volume":"379","author":"Pavlidis","year":"2012","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.canep.2021.102045_bib2","first-page":"1","article-title":"Progress in refining the clinical management of cancer of unknown primary in the molecular era","author":"Rassy","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canep.2021.102045_bib3","article-title":"The diagnostic challenges of patients with carcinoma of unknown primary","volume":"0","author":"Rassy","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.canep.2021.102045_bib4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions","volume":"226","author":"Kuhn","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.canep.2021.102045_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2009.10.003","article-title":"Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review","volume":"75","author":"Pentheroudakis","year":"2010","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canep.2021.102045_bib6","first-page":"652","article-title":"Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging","volume":"31","author":"Singh","year":"2018","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.canep.2021.102045_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"FIGO committee on gynecologic oncology, staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet."},{"key":"10.1016\/j.canep.2021.102045_bib8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ygyno.2015.01.534","article-title":"Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities \u2014 a systematic review","volume":"136","author":"S\u00f8rensen","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canep.2021.102045_bib9","article-title":"Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered","volume":"0","author":"Rassy","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.canep.2021.102045_bib10","unstructured":"NCCN Guidelines (2020). Ovarian Cancer\/Fallopain Tube Cancer\/Primary Peritoneal Cancer. Version 1.2020 [Available at: \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf\u3009]. NCCN Clinical Practice Guidelines in Oncology., (n.d.)."},{"key":"10.1016\/j.canep.2021.102045_bib11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.canep.2021.102045_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.canep.2021.102045_bib13","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.21037\/atm.2020.03.156","article-title":"Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?","volume":"8","author":"Boussios","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.canep.2021.102045_bib14","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program (\u3008www.seer.cancer.gov\u3009) Research Data (1973\u20132015), DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission. Bethesda, MD: National Cancer Institute., (n.d.)."},{"key":"10.1016\/j.canep.2021.102045_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004347-200110000-00005","article-title":"Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma","volume":"20","author":"Halperin","year":"2001","journal-title":"Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol."},{"key":"10.1016\/j.canep.2021.102045_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0046-8177(00)80252-X","article-title":"Identification of a novel 9\u2009cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum","volume":"31","author":"Huang","year":"2000","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canep.2021.102045_bib17","first-page":"490","article-title":"Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum","volume":"55","author":"Muto","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.canep.2021.102045_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jnci\/90.11.841","article-title":"Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations","volume":"90","author":"Schorge","year":"1998","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2021.102045_bib19","doi-asserted-by":"crossref","first-page":"viii61","DOI":"10.1093\/annonc\/mdx443","article-title":"Real-world evidence in the treatment of ovarian cancer","volume":"28","author":"Eisenhauer","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.canep.2021.102045_bib20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00404-014-3364-8","article-title":"The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer","volume":"290","author":"Zeppernick","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.canep.2021.102045_bib21","doi-asserted-by":"crossref","first-page":"viii8","DOI":"10.1093\/annonc\/mdx445","article-title":"The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications","volume":"28","author":"Duska","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canep.2021.102045_bib22","article-title":"Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III\/IV ovarian, tubal, and peritoneal cancers: Japan clinical oncology group study JCOG0206","volume":"113","author":"Takashi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canep.2021.102045_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.canep.2021.102045_bib24","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/PAS.0b013e3181a24354","article-title":"Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis","volume":"33","author":"Ayhan","year":"2009","journal-title":"Am. J. Surg. Pathol."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782121001624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782121001624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:28:13Z","timestamp":1761802093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782121001624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":24,"alternative-id":["S1877782121001624"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2021.102045","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2021.102045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102045"}}